Dr. Russell Scott Akin, MD

Dr. Akin practices at Midland Skin Cancer Center in Midland, Texas.

Dr. Akin's NPI, 1346432440, was assigned on August 13, 2007. Dr. Akin graduated from Texas Tech University Health Sciences Center School of Medicine in 2005. Dr. Akin holds Texas license M6490.

Dr. Akin's primary practice is Midland Skin Cancer Center, at 5117 Sunmore Cir, Midland, TX 79707-5124. The practice phone is (432) 689-2512.

Dr. Akin's primary practice is Midland Skin Cancer Center in Midland, Texas. Dr. Akin is also affiliated with Midland Memorial Hospital. The medical group on file is Midland Dermatology.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Akin practices, 2 sites in all. Vendor and product names are available with a free account.

Mohs-micrographic surgery is Dr. Akin's primary specialty in the NPI Registry, under taxonomy code 207ND0101X. Dr. Akin is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Akin's licenses on file in 3 states: Texas, Oklahoma and Pennsylvania.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, corns and calluses and hives among the conditions Dr. Akin treats.

CMS data shows 7,361 Medicare services from Dr. Akin across 36 procedure codes in 2024, for 1,148 Medicare patients. Medicare paid $557,630 for them. Every service was in an office.

CMS counts 1,148 Medicare patients who saw Dr. Akin in 2024. The largest group is 65 to 74, with 605 patients. 73% of them have high cholesterol, and 72% have high blood pressure. 2% are also on Medicaid. Their average risk score is 0.90, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Akin's median patient age at 72, with 42% women.

In 2024, Dr. Akin wrote 994 Medicare Part D claims for 436 patients. 97% of them were for generic drugs. CMS names the drug for 896 of them, across 17 drugs with 11 or more claims each, at $13,985 in total drug cost. In 2023, CMS named 765 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Akin for performance year 2024, reported as part of a group. Dr. Akin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 1,393 procedures of removal of skin lesions by Dr. Akin, more than 96% of the clinicians it reports for that procedure.

Dmand AI links 9 papers to Dr. Akin, published from 2019 to 2024. The most frequent topics are Carcinoma, Squamous Cell and Skin Neoplasms. Dr. Akin has published most often in Dermatol Surg. Dr. Akin's most frequent co-authors are Michelle Babb Tarbox, MD, Ashley L. Sturgeon, MD and Daniel Bowen Baird, MD.

CMS Open Payments shows 378 general payments to Dr. Akin from 37 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Abbvie Inc. paid the most, $1,509.

Dmand AI lists 2 awards for Dr. Akin.

Dr. Akin graduated from Texas Tech University Health Sciences Center School of Medicine in 2005. Dr. Akin is a member of AAD and ASDS.

Dr. Akin is in network with 9 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.